Abstract: The present invention relates to oral pharmaceutical compositions comprising eluxadoline or a prodrug or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients, and process for the preparation thereof and administration of such compositions for irritable bowel syndrome (IBS-D).

Abstract: The present invention relates to a binder free stable pharmaceutical composition comprising amorphous canagliflozin or a pharmaceutically acceptable salt or a prodrug thereof, and one or more pharmaceutically acceptable excipients, wherein the said composition is devoid of canagliflozin hemihydrate, and having acceptable chemical stability, polymorphic stability & comparative dissolution and bioavailability profile to that of INVOKANA® tablets.

Abstract: The present invention provides dibenzylamine salt of Lifitegrast (XV), and diphenylamine salt of Lifitegrast (XVI) and the use of the above salts in the purification process of Lifitegrast (I). The present invention relates to a process for the preparation of Lifitegrast (I).

Abstract: The present invention provides a process for the preparation of N-phenoxyisopropyl ethanolamine of Formula (II) and its conversion to Phenoxybenzamine of Formula (I) or pharmaceutically acceptable salts thereof.

Abstract: The present invention provides a process for the preparation of vigabatrin of formula (I) comprising of dissolving vigabatrin in water, optionally treating with charcoal, filtering and adding an acid to the reaction mass followed by the addition of an organic solvent and then isolating vigabatrin of formula (I) with high purity.

Abstract: The present invention is directed towards a process for the preparation of Cariprazine (Ia) or a pharmaceutically acceptable salt thereof, wherein, N,N-dimethyl-1H-imidazole-1-carboxamide alkyl halide (VII) is reacted with trans-4-(2-(4-(2,3-dichlorophenyl)piperazin-1-yl)ethyl)cyclohexanamine or a salt thereof (IIa) to produce Cariprazine (Ia) or a pharmaceutically acceptable salt thereof. The present invention is also directed towards amorphous form of Cariprazine hydrochloride (I) and solid dispersion of Cariprazine hydrochloride (I), and its preparation thereof.

Abstract: The present invention provides a process for the preparation of Docosanol (I). The process comprises reducing cis-13-Docosenoic acid (V) to obtain Docosanoic acid (III), which is further reduced to obtain Docosanol (I).

Abstract: A portable self-administrable medication delivery device with “End of Life” feature includes a housing, a drive member within said housing, a locking element and a medicine filled container. The device further provides a “Partial Dose Prevention” feature to deliver an accurate amount of dose with precision. The device is capable of delivering multiple doses of a liquid medicament contained therein without the need of priming the injector prior to administration and allows for repeated administration of a dose of medicament in a simple, easy, safe and accurate manner.

Abstract: The present invention relates to injectable oil in water pharmaceutical composition comprising effective amount of clevidipine or a pharmaceutically acceptable salt or ester as an active agent and process of preparation thereof. The invention also relates to the use of the emulsion in intravenous administration during surgery and postoperatively in hypertension and for short term treatment of hypertension when oral therapy is not feasible or desirable.

Abstract: The present invention relates to a process for the preparation of Tipiracil hydrochloride crystal III, which comprises reaction of Tipiracil with hydrochloric acid in presence of solvent is selected from alcohol and/or water. Further, the present invention relates to pure Tipiracil base having purity greater than about 99.0% by HPLC.

Abstract: The present invention relates to a process For the preparation of Dapagliflozin DL-Proline co-crystal and its use in the preparation/purification of Dapagliflozin. The invention also provides a process for the preparation of Dapagliflozin (R,S)-1.2-propanediol monohydrate.

Abstract: The present invention relates to solid dispersion of Naloxegol oxalate. Further, the present invention relates to an improved process for Naloxegol oxalate and intermediates thereof.

Abstract: The present invention relates to a pharmaceutical composition comprising brexpiprazole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, wherein particle size of brexpiprazole or pharmaceutically acceptable salt thereof is D90 from about 10 ?m to about 40 ?m, particularly D90 is in the range from about 15 ?m to about 30 ?m and process of preparation of said pharmaceutical composition and its use for the adjunctive treatment of major depressive disorder (MDD) and treatment of schizophrenia.

Abstract: The present invention relates to stabilized pharmaceutical formulations comprising therapeutically effective amount of Cariprazine premix/solid dispersion, or its pharmaceutically acceptable salts, esters, hydrates and solvates thereof, at least one diluent which is not having low water activity and optionally one or more excipients selected from lubricant, disintegrant and buffering agent or combinations thereof. The present invention further relates to process for preparation and method of using such stable formulations comprising Cariprazine.

Abstract: The present invention relates to stable premix formulations for parenteral use and packaging for such formulations. The present invention relates to use of a single layer or multilayer film bags comprising polypropylene for packing premixed injectable formulations which remain stable during the storage period. The present invention relates to use of a single layer or multilayer film bags comprising polypropylene for packing dexmedetomidine premixed formulations. Such stable premixed formulations packed into a single layer or multilayer film bags comprising polypropylene are highly advantageous since they are ready-to-use, for example, in perioperative care of a subject in need thereof for sedation.

Abstract: The present invention provides a process for the preparation of N-phenoxyisopropyl ethanolamine of Formula (II) and its conversion to Phenoxybenzamine of Formula (I) or pharmaceutically acceptable salts thereof.

Abstract: The present invention provides a process for the preparation of Docosanol (I). The process comprises reducing cis-13-Docosenoic acid (V) to obtain Docosanoic acid (III), which is further reduced to obtain Docosanol (I).

Abstract: The invention relates to a topical pharmaceutical composition comprising effective amount of ivermectin as an active agent, process of preparation thereof and method of treating dermatological conditions such as inflammatory lesions of rosacea, common acne, seborrheic dermatitis, perioral dermatitis, acne form rashes, and the like.

Abstract: Device for immobilizing contents in a container and more particularly device and a method for immobilizing solid dosage forms such as pills, tablets, capsules or other breakable contents in containers are provided.

Abstract: The present invention relates to stable premix formulations for parenteral use and packaging for such formulations. The present invention relates to use of a single layer or multilayer film bags comprising polypropylene for packing premixed injectable formulations which remain stable during the storage period. The present invention relates to use of a single layer or multilayer film bags comprising polypropylene for packing dexmedetomidine premixed formulations. Such stable premixed formulations packed into a single layer or multilayer film bags comprising polypropylene are highly advantageous since they are ready-to-use, for example, in perioperative care of a subject in need thereof for sedation.